← All trials
NCT00002550
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 1994
- Primary completion
- Jun 1, 2004
- Completion date
- Nov 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 429
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Radiation Therapy Oncology GroupLead sponsor
- Mayo ClinicStudy chair
- Loyola UniversityOverall official - principal investigator
- Johns Hopkins UniversityStudy chair
- Harvard UniversityStudy chair
- Medical University of South CarolinaStudy chair
- Vanderbilt UniversityStudy chair
- National Cancer Institute (NCI)Collaborator
- Southwest Oncology GroupCollaborator
- Eastern Cooperative Oncology GroupCollaborator
- North Central Cancer Treatment GroupCollaborator
- Canadian Cancer Trials GroupCollaborator
- Cancer and Leukemia Group B (CALGB)Collaborator
- Laval UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.